Skip to content

Myelodysplastic Syndromes

Myelodysplastic syndromes (MDS) are bone-marrow cancers in which abnormal stem cells produce too few healthy blood cells. The course ranges from lower-risk disease monitored or supported over time to higher-risk disease that can progress to acute myeloid leukaemia.

Key takeaways

  • Persistent low blood counts have many causes; marrow and genetic testing establish MDS and its subtype.
  • Risk classification estimates progression and helps balance observation, supportive care, disease-modifying treatment and transplant.
  • Fever, bleeding or severe anaemia symptoms can become urgent because healthy blood-cell production is impaired.

The catalogue cannot diagnose MDS or define treatment; blood counts, genetics, symptoms, risk category and transplant fitness guide haematology care.

How is MDS diagnosed?

Repeated blood counts may show anaemia, low neutrophils or low platelets. Marrow examination assesses cell appearance and blast proportion, while chromosome and mutation tests refine diagnosis and risk. Deficiency, medicines and other marrow diseases must be excluded.

What determines treatment?

Lower-risk disease may use monitoring, transfusion or growth-factor support. Lenalidomide has a specific role in selected disease with a chromosome 5q deletion, not MDS generally. Higher-risk treatment and stem-cell transplant decisions belong within oncology support.

When to seek urgent care

Seek urgent help for fever or chills, uncontrolled bleeding, black stool, chest pain, severe breathlessness, fainting, confusion or rapidly worsening weakness. Follow the haematology team’s fever plan during treatment.